Evidence map›Paper›PMID 42804082›Full record

ArticleAdvances in therapy2026

Patient Experience with Treatment of HAE Attacks: Results from a Real-World Survey of Physicians and Their Patients.

John Anderson, Laurence Bouillet, Paula J Busse, Teresa Caballero, Mar Guilarte, Michihiro Hide, Ramón Lleonart, William R Lumry, Markus Magerl, Marc A Riedl and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

John AndersonAllerVie Health, and Birmingham VA Medical Center, Birmingham, AL, USA.
Laurence BouilletService de Médecine Interne, Centre de Référence des Angioœdèmes, CHU Grenoble Alpes, Grenoble, France.
Paula J BusseDepartment of Medicine, Allergy and Immunology, Mount Sinai Hospital, New York, NY, USA.
Teresa CaballeroDepartment of Allergy, Biomedical Research Network On Rare Diseases (CIBERER, U754), Hospital La Paz Institute for Health Research (IdiPAZ), Hospital Universitario La Paz, Madrid, Spain.
Mar GuilarteDepartment of Allergy, Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Michihiro HideDepartment of Dermatology, Hiroshima University and Hiroshima City Hospital Organization, Hiroshima, Japan.
Ramón LleonartAllergology Department, L'Hospitalet de Llobregat, Bellvitge University Hospital, Barcelona, Spain.
William R LumryAARA Research Center, Dallas, TX, USA.
Markus MagerlInstitute of Allergology, Charité-University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Marc A RiedlDivision of Allergy and Immunology, University of California, San Diego, La Jolla, CA, USA.
Patrick F K YongFrimley Health NHS Foundation Trust, Frimley, Surrey, UK.
Andrea ZanichelliDipartimento di Scienze Biomediche per la Salute, Universita degli Studi di Milano, Milan, Italy.
Hannah ConnollyAdelphi Real World, Bollington, UK.
Maggie ChenPharvaris Inc., Lexington, MA, USA.
Joan MendivilPharvaris GmbH, Grafenauweg 8, 6300, Zug, Switzerland. joan.mendivil@pharvaris.com.ORCID http://orcid.org/0000-0003-1139-0078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable, and potentially life-threatening angioedema attacks. Few reports describing physician and patient perspectives on their experiences with HAE, long-term prophylaxis (LTP), and on-demand treatment regimens exist. This analysis aimed to address remaining critical gaps, particularly regarding patient attitudes toward treatment adherence, symptom experience, and timing to relief onset, by capturing physician and patient insights on these topics.

methodsData are from the Adelphi Real World HAE Disease Specific Programme™, a cross-sectional, retrospective survey of physicians and their patients conducted across Europe, Japan, and the US from January 2023 through January 2024. Surveyed physicians were directly involved in the management of at least two patients with HAE per month. Eligible patients had experienced at least one attack since diagnosis. Physicians completed an online Patient Record Form (PRF) based on data from patients' medical charts and their clinical judgment. Each patient with a physician-completed form was invited to complete a voluntary self-reported questionnaire.

resultsParticipating physicians (n = 225) completed PRFs for 1131 patients (age range: 3-82 years); 279 patients completed the questionnaire. Most patients were female (physician reported: 607/1131 [54%]; patient reported: 145/279 [52%]). Overall, 48% of patients in the physician-reported groups and 51% in the patient-reported group experienced one to two attacks during the 12 months before the survey. The top reason for not treating the most recent attack was perceiving it as mild/not severe or limiting (physician reported: 54%; patient reported: 59%). The top reason for suboptimal adherence to LTP in the physician- and patient-reported groups was forgetting to take medication (45% and 51%, respectively).

conclusionThis analysis increases our understanding of the lived experience of HAE and helps address the remaining gaps in treatment satisfaction and adherence within the HAE community.

Indexed as

Angioedema attacksEvidence outcomes and researchHereditary angioedemaLong-term prophylaxisOn-demand treatmentPatient perspectivesPhysician perspectivesReal-world evidenceTreatment patternsTreatment satisfaction

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.